Calidi Biotherapeutics (NYSE:CLDI – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($1.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.43) by $0.03, Yahoo Finance reports.
Calidi Biotherapeutics Stock Up 3.1 %
Shares of NYSE CLDI traded up $0.05 during trading on Thursday, reaching $1.65. The company had a trading volume of 3,833 shares, compared to its average volume of 154,692. Calidi Biotherapeutics has a 52 week low of $1.41 and a 52 week high of $137.90.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on the stock. LADENBURG THALM/SH SH assumed coverage on shares of Calidi Biotherapeutics in a report on Thursday, June 27th. They set a “buy” rating and a $10.00 price target for the company. Robert W. Baird cut their price target on shares of Calidi Biotherapeutics from $45.00 to $20.00 and set an “outperform” rating for the company in a report on Wednesday, May 15th.
Calidi Biotherapeutics Company Profile
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer with a novel stem cell-based therapy. Calidi Biotherapeutics Inc, formerly known as First Light Acquisition Group, is based in SAN DIEGO.
Further Reading
- Five stocks we like better than Calidi Biotherapeutics
- How Can Investors Benefit From After-Hours Trading
- Why You Shouldn’t Count Out Tencent Music Stock After Earnings
- Energy and Oil Stocks Explained
- Why Meta Could Be A $600 Stock Within Weeks
- Investing in Commodities: What Are They? How to Invest in Them
- Conservative Portfolio: Strategies for Stability
Receive News & Ratings for Calidi Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calidi Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.